In 2017, Banerjee et al. [170] published the result of a phase I study to assess the dose-limiting toxicities and antitumor activity of selumetinib, a MEK inhibitor [171], in children with progressive low-grade gliomas (LGGs). The gene discussed is MAP2K7; the disease is low grade glioma.